Radius Health Inc. buy tamam
Start price
30.01.18
/
50%
€35.46
Target price
04.11.21
€21.41
Performance (%)
-47.87%
End price
05.11.21
€18.49
Summary
This prediction ended on 05.11.21 with a price of €18.49. Massive losses of -47.87% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Radius Health Inc. | - | - | - | - |
| iShares Core DAX® | -1.553% | -0.123% | 12.654% | 57.846% |
| iShares Nasdaq 100 | -0.386% | -0.595% | 4.546% | 93.736% |
| iShares Nikkei 225® | 1.640% | 5.468% | 17.939% | 51.788% |
| iShares S&P 500 | 0.114% | -0.217% | 1.586% | 61.648% |
Comments by tamam for this prediction
In the thread Radius Health Inc. diskutieren
Radius Health could Advance 50% With Osteoporosis Treatment
Morgan Stanley analyst initiated coverage of the company with an Overweight rating and a $57 price target.
Radius is set to launch Tymlos, a bone builder for women with osteoporosis, but despite Eli Lilly's presence in the market with Forteo, which fetched the company $1 billion in sales and is exposed to generic competition in 2019, the analyst said Tymlos' pricing is 40 percent lower than Forteo's — and
convenience could help it grab share.
Radius Health is a Conviction Buy!
Kursziel geändert auf 41,414
Kursziel geändert auf 21,414
In the thread Trading Radius Health Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten